抗生素抗药性市场：机会、成长要素、产业趋势分析及2026年至2035年预测

2025 年全球抗生素抗药性市场价值为 99 亿美元，预计到 2035 年将达到 187 亿美元，年复合成长率为 6.7%。

抗菌素抗药性（AMR）的日益恶化是推动这一市场成长的主要因素，而抗菌素抗药性已成为全球医疗保健系统面临的主要挑战。多重抗药性感染疾病的不断增加，使得人们迫切需要新型抗生素、快速诊断方案和创新治疗方法。抗生素的滥用和过度使用、医院感染的蔓延以及抗药性病原体的出现，都在推动新治疗方法的研究和投资。人口老化、外科手术的增加以及慢性病盛行率的上升，都增加了感染风险，凸显了病人安全和医疗成本控制的重要性。各国政府、卫生部门和製药公司正在积极推行抗菌药​​物管理计画、监管奖励和资金筹措倡议，意识提升也促进了市场扩张。

预计到2025年，复杂性尿道感染（cUTI）将占泌尿道感染总数的30.2%，反映了其高发生率和临床复杂性。患有糖尿病和肾臟病等潜在疾病的患者尤其容易感染cUTI，这也推高了对先进抗生素治疗的需求。 cUTI通常与多重抗药性病原体相关，需要频谱治疗以缩短住院时间并最大限度地减少併发症。临床指南和研究倡议不断推动有效治疗通讯协定的製定，并促进能够有效对抗抗药性菌株的新疗法的引入。

预计到2025年，大肠桿菌（E. coli）市占率将达到23.4%，呈现显着成长趋势。大肠桿菌感染疾病构成重大的公共卫生挑战，常导致严重的胃肠道疾病和併发症，进而增加医疗成本。感染率的上升及其带来的医疗保健负担，特异性推动着针对多重抗药性大肠桿菌菌株的治疗方法和诊断方法的投资增加，凸显了该细分市场在更广泛的抗生素抗药性市场中的关键作用。

预计到2025年，美国抗生素抗药性市场规模将达37亿美元。凭藉完善的医疗基础设施、严格的监测系统以及对抗生素使用计画的巨额投资，美国已成为全球最先进的市场之一。抗药性病原体（例如抗药性金黄色葡萄球菌和铜绿假单胞菌）的高盛行率持续推动对快速诊断和创新治疗方法的需求，使美国成为全球市场的主要驱动力。

目录

第一章：调查方法和范围

第二章执行摘要

第三章业界考察

• 生态系分析
  • 供应商情况
  • 影响价值链的因素
• 影响产业的因素
  • 促进因素
    • 抗生素抗药性感染疾病发生率增加
    • 加大对新型抗生素研发的投入
    • 对新型抗生素疗法的需求日益增长
    • 全球公共卫生议题和意识日益增强
  • 产业潜在风险与挑战
    • 对新药的抗药性迅速出现
    • 复杂的法规和发展过程
  • 市场机会
    • 开发下一代抗生素和替代疗法
• 成长潜力分析
• 监管环境
  • 北美洲
  • 欧洲
  • 亚太地区
• 科技趋势
  • 当前技术趋势
  • 新兴技术
• 未来市场趋势
• 专利分析
• 波特五力分析
• PESTEL 分析

第四章 竞争情势

• 介绍
• 企业市占率分析
  • 世界
  • 北美洲
  • 欧洲
• 公司矩阵分析
• 主要市场公司的竞争分析
• 竞争定位矩阵
• 主要进展
  • 併购
  • 伙伴关係与合作
  • 新产品发布
  • 扩张计划

第五章 市场估算与预测：依疾病分类，2022-2035年

• 复杂性尿道感染
• 复杂性腹腔内感染疾病
• 血液感染疾病
• 急性细菌性皮肤及皮肤组织感染疾病
• 社区型细菌性肺炎
• 医院获得性细菌性肺炎

第六章 市场估算与预测：依病原体划分，2022-2035年

• 大肠桿菌
• 肺炎克雷伯菌
• 铜绿假单胞菌
• 金黄色葡萄球菌
• 鲍曼 -鲍氏静止桿菌
• 肺炎链球菌
• 流感细菌

第七章 市场估计与预测：依药物类别划分，2022-2035年

• Oxazolidinone系列
• 头孢菌素
• 醣肽
• 联合治疗
• 四环霉素
• 其他药物类别

第八章 市场估算与预测：依作用机制划分，2022-2035年

• 细胞壁合成抑制剂
• 蛋白质合成抑制剂
• DNA合成抑制剂
• RNA合成抑制剂
• 其他作用机制

第九章 市场估价与预测：依通路划分，2022-2035年

• 医院药房
• 零售药房
• 网路药房

第十章 市场估价与预测：依地区划分，2022-2035年

• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国

第十一章：公司简介

• AbbVie
• Basilea Pharmaceutical
• Bayer AG
• Merck and Co.
• Melinta Therapeutics
• Johnson & Johnson
• Paratek Pharmaceuticals
• Pfizer
• Shionogi & Co., Ltd.
• Tetraphase Pharmaceuticals
• Wockhardt

The Global Antibiotic Resistance Market was valued at USD 9.9 billion in 2025 and is estimated to grow at a CAGR of 6.7% to reach USD 18.7 billion by 2035.

The market is fueled by the escalating global crisis of antimicrobial resistance (AMR), which has become a major concern for healthcare systems worldwide. The increasing incidence of multidrug-resistant infections has created a pressing demand for novel antibiotics, rapid diagnostic solutions, and innovative treatment options. Misuse and overuse of antibiotics, the prevalence of hospital-acquired infections, and the emergence of resistant pathogens are driving research and investment into new therapies. The growing elderly population, higher surgical interventions, and the rising prevalence of chronic diseases are heightening infection risks, emphasizing patient safety and healthcare cost management. Governments, health authorities, and pharmaceutical firms are promoting stewardship programs, regulatory incentives, and funding initiatives, while increased awareness among healthcare professionals and patients supports the market's expansion.

The complicated urinary tract infections (cUTIs) segment accounted for 30.2% share in 2025, reflecting their high prevalence and clinical complexity. Patients with underlying health conditions such as diabetes or kidney disorders are particularly vulnerable, which boosts the demand for advanced antibiotic therapies. cUTIs often involve multidrug-resistant pathogens, necessitating broad-spectrum treatments to reduce hospital stays and minimize complications. Clinical guidelines and research initiatives continue to shape effective treatment protocols, driving the adoption of newer therapies capable of addressing resistant strains efficiently.

The Escherichia coli (E. coli) segment captured 23.4% share in 2025 and is anticipated to see substantial growth. E. coli infections pose significant public health challenges, often resulting in severe gastrointestinal illness and complications that can escalate healthcare costs. Rising outbreaks and the associated healthcare burden are motivating increased investment in therapies and diagnostics that specifically target multidrug-resistant E. coli strains, highlighting the critical role of this segment within the broader antibiotic resistance market.

U.S Antibiotic Resistance Market reached USD 3.7 billion in 2025. The country represents one of the most advanced markets globally, supported by a robust healthcare infrastructure, stringent surveillance systems, and significant investment in antimicrobial stewardship programs. The high prevalence of multidrug-resistant pathogens, including resistant Staphylococcus aureus and Pseudomonas aeruginosa strains, continues to drive demand for rapid diagnostics and innovative therapies, positioning the U.S. as a key growth driver in the global market.

Major players in the Global Antibiotic Resistance Market include Wockhardt, Johnson & Johnson, AbbVie, Pfizer, Paratek Pharmaceuticals, Bayer AG, Melinta Therapeutics, Shionogi & Co., Ltd., Tetraphase Pharmaceuticals, and Basilea Pharmaceutical. Companies in the antibiotic resistance market are employing several strategies to strengthen their presence and market position. They are investing heavily in research and development to discover novel antibiotics and therapies capable of combating multidrug-resistant pathogens. Strategic partnerships and collaborations with healthcare institutions, academic organizations, and government bodies help accelerate clinical trials and regulatory approvals. Firms are also focusing on expanding their global footprint, particularly in regions with high AMR prevalence. Investments in rapid diagnostic technologies and companion therapies enhance treatment efficacy and patient outcomes.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Disease trends
  • 2.2.2 Pathogen trends
  • 2.2.3 Drug class trends
  • 2.2.4 Mechanism of action trends
  • 2.2.5 Distribution channel trends
  • 2.2.6 Regional trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Factors affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of antibiotic-resistant infections
    • 3.2.1.2 Increasing investments for research and development of novel antibiotics
    • 3.2.1.3 Growing need for new antibiotic therapies
    • 3.2.1.4 Increasing global public health concern and awareness
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Rapid emergence of resistance to new drugs
    • 3.2.2.2 Complex regulatory and development process
  • 3.2.3 Market opportunities
    • 3.2.3.1 Development of next-generation antibiotics and alternative therapies
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Technology landscape
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Future market trends
• 3.7 Patent analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 Global
  • 4.2.2 North America
  • 4.2.3 Europe
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Disease, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Complicated urinary tract infections
• 5.3 Complicated intra-abdominal infections
• 5.4 Bloodstream infections
• 5.5 Acute bacterial skin and skin-structure infections
• 5.6 Community-acquired bacterial pneumonia
• 5.7 Hospital-acquired bacterial pneumonia

Chapter 6 Market Estimates and Forecast, By Pathogen, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 E. coli - Escherichia coli
• 6.3 K. pneumoniae - Klebsiella pneumoniae
• 6.4 P. aeruginosa - Pseudomonas aeruginosa
• 6.5 S. aureus - Staphylococcus aureus
• 6.6 Baumannii - Acinetobacter baumannii
• 6.7 S. pneumoniae - Streptococcus pneumoniae
• 6.8 H. influenzae

Chapter 7 Market Estimates and Forecast, By Drug Class, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Oxazolidinones
• 7.3 Cephalosporin
• 7.4 Lipoglycopeptides
• 7.5 Combination therapies
• 7.6 Tetracyclines
• 7.7 Other drug classes

Chapter 8 Market Estimates and Forecast, By Mechanism of Action, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Cell wall synthesis inhibitors
• 8.3 Protein synthesis inhibitors
• 8.4 DNA synthesis inhibitors
• 8.5 RNA synthesis inhibitors
• 8.6 Other mechanism of actions

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 Hospital pharmacies
• 9.3 Retail pharmacies
• 9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 India
  • 10.4.3 Japan
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 AbbVie
• 11.2 Basilea Pharmaceutical
• 11.3 Bayer AG
• 11.4 Merck and Co.
• 11.5 Melinta Therapeutics
• 11.6 Johnson & Johnson
• 11.7 Paratek Pharmaceuticals
• 11.8 Pfizer
• 11.9 Shionogi & Co., Ltd.
• 11.10 Tetraphase Pharmaceuticals
• 11.11 Wockhardt